Pub Date : 2012-12-01DOI: 10.1097/FAD.0b013e32835ccbf1
Christopher M. Jones, J. Pascoe, J. Coleman
SummaryMonoclonal agents have been developed to specifically target cancer cells but they can have systemic adverse effects which can be life-threatening, particularly infusion reactions, immunosuppression, tumour lysis syndrome, profound hypertension, cardiac failure and haematological toxicity.
{"title":"Adverse reactions to monoclonal agents used in the treatment of cancer","authors":"Christopher M. Jones, J. Pascoe, J. Coleman","doi":"10.1097/FAD.0b013e32835ccbf1","DOIUrl":"https://doi.org/10.1097/FAD.0b013e32835ccbf1","url":null,"abstract":"SummaryMonoclonal agents have been developed to specifically target cancer cells but they can have systemic adverse effects which can be life-threatening, particularly infusion reactions, immunosuppression, tumour lysis syndrome, profound hypertension, cardiac failure and haematological toxicity.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"277 1","pages":"1067–1070"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e32835ccbf1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-10-01DOI: 10.1097/FAD.0b013e32835aa06d
R. Ferner
SummaryDrug-induced haemolytic anaemia is a rare adverse effect. Drugs implicated include &bgr;-lactam antibiotics, co-trimoxazole, ciprofloxacin, fludarabine, lorazepam and diclofenac. Men with G6PD deficiency are at greater risk of developing drug-induced haemolytic anaemia with a greater range of drugs.
{"title":"Drug-induced haemolytic anaemia","authors":"R. Ferner","doi":"10.1097/FAD.0b013e32835aa06d","DOIUrl":"https://doi.org/10.1097/FAD.0b013e32835aa06d","url":null,"abstract":"SummaryDrug-induced haemolytic anaemia is a rare adverse effect. Drugs implicated include &bgr;-lactam antibiotics, co-trimoxazole, ciprofloxacin, fludarabine, lorazepam and diclofenac. Men with G6PD deficiency are at greater risk of developing drug-induced haemolytic anaemia with a greater range of drugs.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"16 1","pages":"1063–1066"},"PeriodicalIF":0.0,"publicationDate":"2012-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e32835aa06d","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-08-01DOI: 10.1097/FAD.0b013e3283581e14
F. Oates, Fouad Siddiqui
SummaryDrug-induced parkinsonism is common. Many drugs are implicated, particularly typical and atypical antipsychotics, antidepressants, anticonvulsants and certain antiemetics and antihypertensives. Identifying the offending drug is important in reducing morbidity.
{"title":"Drug-induced movement disorders","authors":"F. Oates, Fouad Siddiqui","doi":"10.1097/FAD.0b013e3283581e14","DOIUrl":"https://doi.org/10.1097/FAD.0b013e3283581e14","url":null,"abstract":"SummaryDrug-induced parkinsonism is common. Many drugs are implicated, particularly typical and atypical antipsychotics, antidepressants, anticonvulsants and certain antiemetics and antihypertensives. Identifying the offending drug is important in reducing morbidity.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"275 1","pages":"1059–1062"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e3283581e14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-04-01DOI: 10.1097/FAD.0b013e328353e4a9
Chih-Chien Sung, Shih-Hua Lin
SummaryDrug-induced hypokalaemia is common in therapeutic dose and overdose. It arises via several mechanisms that can be simply divided based on urine potassium excretion rate. When the urinary potassium excretion is low, drugs can induce hypokalaemia by acute transcellular potassium shift (&bgr;2-adrenergic agonists, insulin, thyroxine, calcium-channel blockers, thiopental sodium, chloroquine), gastrointestinal tract potassium loss (laxatives, drug-induced diarrhoea and vomiting, cation-exchange resin), or former renal potassium wasting (diuretics ‘off’ action). The drugs that induce hypokalaemia because of high urine potassium excretion rate can cause excessive mineralocorticoid effects (hydrocortisone, licorice), or renal tubular defects with either metabolic alkalosis (diuretics, antibiotics with nonreabsorbale anions, aminoglycoside, cisplatin) or metabolic acidosis (carbonic anhydrase inhibitor, antiretrovirals, antifungal drugs, aristolochic acid, chemotherapy). The management of drug-induced hypokalaemia incorporates assessment of the onset and degree of hypokalaemia, cessation of the culprit drug, consideration of potassium replacement, assessment of the risk of potassium therapy, and management of associated illness. Early recognition of drug-induced hypokalaemia with prompt management is still the key to avoid potential life-threatening complications.
{"title":"Drug-induced hypokalaemia: Part 1","authors":"Chih-Chien Sung, Shih-Hua Lin","doi":"10.1097/FAD.0b013e328353e4a9","DOIUrl":"https://doi.org/10.1097/FAD.0b013e328353e4a9","url":null,"abstract":"SummaryDrug-induced hypokalaemia is common in therapeutic dose and overdose. It arises via several mechanisms that can be simply divided based on urine potassium excretion rate. When the urinary potassium excretion is low, drugs can induce hypokalaemia by acute transcellular potassium shift (&bgr;2-adrenergic agonists, insulin, thyroxine, calcium-channel blockers, thiopental sodium, chloroquine), gastrointestinal tract potassium loss (laxatives, drug-induced diarrhoea and vomiting, cation-exchange resin), or former renal potassium wasting (diuretics ‘off’ action). The drugs that induce hypokalaemia because of high urine potassium excretion rate can cause excessive mineralocorticoid effects (hydrocortisone, licorice), or renal tubular defects with either metabolic alkalosis (diuretics, antibiotics with nonreabsorbale anions, aminoglycoside, cisplatin) or metabolic acidosis (carbonic anhydrase inhibitor, antiretrovirals, antifungal drugs, aristolochic acid, chemotherapy). The management of drug-induced hypokalaemia incorporates assessment of the onset and degree of hypokalaemia, cessation of the culprit drug, consideration of potassium replacement, assessment of the risk of potassium therapy, and management of associated illness. Early recognition of drug-induced hypokalaemia with prompt management is still the key to avoid potential life-threatening complications.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"273 1","pages":"1051–1054"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e328353e4a9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-02-01DOI: 10.1097/FAD.0b013e32835142b4
F. Kinsella
Summary Platelet dysfunction and destruction can be induced by several different drug-related mechanisms, and can result in mild-to-severe haemorrhage. Here, the mechanisms mediating these processes are outlined, and the drug classes responsible highlighted.
{"title":"Drug-induced platelet disorders","authors":"F. Kinsella","doi":"10.1097/FAD.0b013e32835142b4","DOIUrl":"https://doi.org/10.1097/FAD.0b013e32835142b4","url":null,"abstract":"Summary Platelet dysfunction and destruction can be induced by several different drug-related mechanisms, and can result in mild-to-severe haemorrhage. Here, the mechanisms mediating these processes are outlined, and the drug classes responsible highlighted.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"&NA; 1","pages":"1047–1050"},"PeriodicalIF":0.0,"publicationDate":"2012-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e32835142b4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-12-01DOI: 10.1097/FAD.0b013e32834eca66
M. Pucci
Summary Drug-induced hyperkalemia is an important cause of morbidity and mortality. Drugs can cause hyperkalemia by a variety of mechanisms including reduction in renal potassium excretion due to hypoaldosteronism, reduction in passive potassium excretion, increase in extracellular potassium shifts and increase in potassium supply. Patients most at risk are those with underlying disorders affecting potassium handling, such as chronic renal failure, and those taking a combination of drugs known to cause hyperkalemia.
{"title":"Mechanisms of drug-induced hyperkalemia","authors":"M. Pucci","doi":"10.1097/FAD.0b013e32834eca66","DOIUrl":"https://doi.org/10.1097/FAD.0b013e32834eca66","url":null,"abstract":"Summary Drug-induced hyperkalemia is an important cause of morbidity and mortality. Drugs can cause hyperkalemia by a variety of mechanisms including reduction in renal potassium excretion due to hypoaldosteronism, reduction in passive potassium excretion, increase in extracellular potassium shifts and increase in potassium supply. Patients most at risk are those with underlying disorders affecting potassium handling, such as chronic renal failure, and those taking a combination of drugs known to cause hyperkalemia.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"&NA; 1","pages":"1043–1046"},"PeriodicalIF":0.0,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e32834eca66","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61685216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-10-01DOI: 10.1097/FAD.0b013e32834d17dc
A. Pariente, C. N. A. Chakra, M. Pinet, Lenhangmbong Nkeng, N. Moore, Y. Moride
Summary Case studies are recognized as important tools for monitoring drug safety, particularly after the drug is licensed and being used widely. Recently, criteria have been formulated to ensure that published case reports and case series are robust, but these are not always met in practice.
{"title":"The value of case series in adverse drug reaction assessment","authors":"A. Pariente, C. N. A. Chakra, M. Pinet, Lenhangmbong Nkeng, N. Moore, Y. Moride","doi":"10.1097/FAD.0b013e32834d17dc","DOIUrl":"https://doi.org/10.1097/FAD.0b013e32834d17dc","url":null,"abstract":"Summary Case studies are recognized as important tools for monitoring drug safety, particularly after the drug is licensed and being used widely. Recently, criteria have been formulated to ensure that published case reports and case series are robust, but these are not always met in practice.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"&NA; 1","pages":"1039–1042"},"PeriodicalIF":0.0,"publicationDate":"2011-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e32834d17dc","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61685207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-08-01DOI: 10.1097/FAD.0b013e32834b1839
K. Stewart
Summary Drug-induced bradycardia is a common adverse effect as well as a desired effect of therapeutic treatment. Interactions between drugs in patients who may be taking many agents are also an important factor. Both cardiac and noncardiac drugs have been shown to cause bradycardia.
{"title":"Drug-induced bradycardia","authors":"K. Stewart","doi":"10.1097/FAD.0b013e32834b1839","DOIUrl":"https://doi.org/10.1097/FAD.0b013e32834b1839","url":null,"abstract":"Summary Drug-induced bradycardia is a common adverse effect as well as a desired effect of therapeutic treatment. Interactions between drugs in patients who may be taking many agents are also an important factor. Both cardiac and noncardiac drugs have been shown to cause bradycardia.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"&NA; 1","pages":"1035–1038"},"PeriodicalIF":0.0,"publicationDate":"2011-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e32834b1839","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-06-01DOI: 10.1097/FAD.0b013e328348c804
S. E. McDowell
Drugs used to treat Alzheimer's disease. Their adverse effects include abdominal pain, anorexia, dizziness, nausea, vomiting, diarrhoea, headache and insomnia.
用于治疗阿尔茨海默病的药物。它们的副作用包括腹痛、厌食、头晕、恶心、呕吐、腹泻、头痛和失眠。
{"title":"Adverse reactions to drugs used in the treatment of Alzheimer's disease","authors":"S. E. McDowell","doi":"10.1097/FAD.0b013e328348c804","DOIUrl":"https://doi.org/10.1097/FAD.0b013e328348c804","url":null,"abstract":"Drugs used to treat Alzheimer's disease. Their adverse effects include abdominal pain, anorexia, dizziness, nausea, vomiting, diarrhoea, headache and insomnia.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"&NA; 1","pages":"1031–1034"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e328348c804","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-04-01DOI: 10.1097/FAD.0b013e328346f575
C. Anton
Botulinum toxin is used to treat cerebral palsy, dystonia, hyperhidrosis, and other conditions, as well as in cosmetic procedures. Although deaths and serious adverse reactions are rare, minor and transient reactions related to the injection site or technique of the operator are commoner.
{"title":"Botulinum toxins: adverse effects","authors":"C. Anton","doi":"10.1097/FAD.0b013e328346f575","DOIUrl":"https://doi.org/10.1097/FAD.0b013e328346f575","url":null,"abstract":"Botulinum toxin is used to treat cerebral palsy, dystonia, hyperhidrosis, and other conditions, as well as in cosmetic procedures. Although deaths and serious adverse reactions are rare, minor and transient reactions related to the injection site or technique of the operator are commoner.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"&NA; 1","pages":"1027–1030"},"PeriodicalIF":0.0,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0b013e328346f575","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61684742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：